title: Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.
abstract: OBJECTIVE
  The aim of this study was to assess the effect of angiotensin-converting enzyme (ACE) inhibition with enalapril on forearm endothelial function in subjects with type II diabetes mellitus.
  
  
  BACKGROUND
  Endothelial function is depressed in the presence of conventional risk factors for atherosclerosis, and various therapies, such as lipid-lowering therapy in hypercholesterolemia, can improve endothelial-mediated vasodilation. ACE inhibition has improved such function in several conditions including type I diabetes, but there is no evidence for a beneficial effect in type II diabetes.
  
  
  METHODS
  The influence of enalapril (10 mg twice daily for 4 weeks) on endothelium-dependent and -independent vasodilator function was determined in 10 type II diabetic subjects using a double-blinded placebo-controlled crossover protocol. Forearm blood flow was measured using strain-gage plethysmography and graded intrabrachial infusion of acetylcholine (ACh), N(G)-monomethyl-L-arginine (LNMMA) and sodium nitroprusside (SNP).
  
  
  RESULTS
  Enalapril increased the response to the endothelium-dependent vasodilator, ACh (p < 0.02) and the vasoconstrictor response to the nitric oxide (NO) synthase inhibitor, LNMMA (p < 0.002). No difference was evident in the response to SNP.
  
  
  CONCLUSIONS
  In type II diabetic subjects without evidence of vascular disease, the ACE inhibitor enalapril improved stimulated and basal NO-dependent endothelial function. The study extends the spectrum of beneficial effects demonstrated to result from ACE inhibition in diabetes.
authors.affiliation: Department of Cardiology, Royal Perth Hospital, Nedlands, Australia.
authors.forename: G
authors.initials: G
authors.lastname: O'Driscoll
authors.forename: D
authors.initials: D
authors.lastname: Green
authors.forename: A
authors.initials: A
authors.lastname: Maiorana
authors.forename: K
authors.initials: K
authors.lastname: Stanton
authors.forename: F
authors.initials: F
authors.lastname: Colreavy
authors.forename: R
authors.initials: R
authors.lastname: Taylor
mesh_terms: D000109:Acetylcholine; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004656:Enalapril / Q000008:administration & dosage* / Q000009:adverse effects; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005542:Forearm / Q000098:blood supply; D006801:Humans; D008875:Middle Aged; D009599:Nitroprusside; D019323:omega-N-Methylarginine
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D009599:Nitroprusside; D019323:omega-N-Methylarginine; D004656:Enalapril; D000109:Acetylcholine